Scholar Rock Holding UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Everyone, thank you for joining us on our next session here at the UBS Global Biopharma Conference. I'm Michael Yee, senior biotechnology analyst at UBS, and very thrilled to have up here the chairman and chief executive officer of Scholar Rock, David Hallal. It's great to have you here.
Great to be here with you, Mike.
Thank you so much. If you have any other questions that we can answer, we got the whole team here also with us at the front of the room. David, congratulations. Obviously, the approval and the launch of ISEMBYLD, I call it the anti-myostatin, apitegromab.
Right. I've been following this drug since it was pre-clinical, so we go way back, and I followed this story.
I'm still getting used to the name, ISEMBYLD.
Right. But maybe if you could just set the table for us.
Obviously, talk a little bit about the recent approval and specifically the early launch, because that is exactly where you guys are, an exciting time period for Scholar Rock. And maybe just set the table for that, and we will talk a little bit about the opportunity for ISEMBYLD.
Sure. Mike, you and I have both been around this story for a while.
Yes. I am in my 10th year now Okay at Scholar Rock, and we are gratified to be at this position of eight weeks post-U.S. approval for ISEMBYLD.
And we are very encouraged by our first eight weeks in the marketplace.
Okay. And look, there were a few dynamics for us that really laid groundwork for what we expect to be a very positive launch.
Okay. First and foremost was, as we have noted, the number one need in the 2026 Cure SMA survey amongst all SMA patients was muscle strength.
You combine that with three-quarters of neurologists have an appreciation that the future of treating SMA patients is by addressing both the motor neuron with SMN-targeted therapies and the muscle with an anti-myostatin, apitegromab, or as you and I now call it, ISEMBYLD. That is a nice setup for us. Secondly, the label. We were thrilled and gratified that the FDA recognized the breadth of patients that could benefit from ISEMBYLD therapy, and our approval covers all patients two years of age and older who are currently receiving an SMN2-targeted therapy. And we estimate that that is about 6,600 patients in the U.S. today.
A very broad label. That was an important thing.
Which we were very pleased to see. Then lastly, I would just say that this is an experienced marketplace. All 6,600 of those patients are on either Evrysdi, SPINRAZA, or HD SPINRAZA. So they and their healthcare teams, their physicians, are extremely experienced with the path to access and reimbursement. So that lays the groundwork quite nicely for us as we launched in mid-September to be able to start the process to generate demand for. We are pleased with both the volume and the breadth of demand so far.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
